Y-L. Wu - Guangdong Academy of Medical Sciences

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 67 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

75P PD-L1 expression and TMB guided first-line sintilimab monotherapy for advanced NSCLC in a multi-center, phase II umbrella trial (CTONG 1702)

S-Y.M. Liu, Q. Zhou, Y. Du, X-R. Dong, C-R. Xu,Y-L. Sun, M-Y. Zheng, J. Huang,Y-S. Li, J. Cui,B. Wang, S. Cang,

ESMO Open (2024)

引用0浏览0引用

103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)

F. Barlesi, E. Felip, S. Popat, B. Solomon, J. Wolf, B.T. Li,Y-L. Wu, K.M. Kerr, H. Akamatsu, D.R. Camidge, R. Gupta, A. Meloni,

ESMO Open (2024)

引用0浏览0引用

34P Updated data from Beamion LUNG-1, a phase (ph) Ia/b trial of the HER2-specific tyrosine kinase inhibitor (TKI), zongertinib (BI 1810631), in patients (pts) with HER2 mutation-positive (m+) NSCLC

Y-L. Wu, F. Opdam, M. Barve, H. Tu, D. Berz, M. Rohrbacher, B. Sadrolhefazi, J. Serra, K. Yoh, N. Yamamoto, J. Heymach

ESMO Open (2024)

引用0浏览0引用

49P Perioperative circulating tumor DNA redefines induced oligometastatic non-small cell lung cancer at the molecular level

R. Fu, Y-Y. Xiong, M. Cai, F. Li, R. Chen,Y-L. Wu,W-Z. Zhong

ESMO Open (2024)

引用0浏览0引用

111P Enhancing negative predictive value of landmark undetectable molecular residual disease with baseline cell free DNA features based XGBoost model in resected non-small cell lung cancer

J-T. Zhang, Z-C. Jiao, S. Dong, X. Gao, Y. Pan, X. Yang, X. Yi, Q. Zhou,W-Z. Zhong,Y-L. Wu

ESMO Open (2024)

引用0浏览0引用

237P Genomic profiling of aggressive pathologic features in lung adenocarcinoma

Y-D. Lin, H. Li, H. Hong, Y. Qi,Y-L. Wu,W-Z. Zhong

ESMO Open (2024)

引用0浏览0引用

74P Five-year survival outcomes of camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic NSCLC: A phase II study

J-J. Yang, C. Huang, Y. Fan, H. Pan,J. Feng, L. Jiang, X. Li, X-Q. Liu, J-P. Xiong,Y. Zhao,Y. Cheng, R. Ma,

ESMO Open (2024)

引用0浏览0引用

42P Pembrolizumab vs chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥1%: 5-year update from KEYNOTE-042

Y-L. Wu, L. Zhang, Y. Fan, J. Zhou, L. Zhang, Q. Zhou,W. Li, C. Hu, G. Chen, X. Zhang, C. Zhou, C.G. Arenas,

JOURNAL OF THORACIC ONCOLOGY（2023）

引用0浏览0引用

20P Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small cell lung cancer with central nervous system metastases in a multi-center, phase II umbrella trial (CTONG1702)

S-Y.M. Liu, Q. Zhou, C. Lu, J-Y. Deng, Z. Wang,Y-S. Li, M-M. Zheng,B-F. Xu,X-R. Dong, Y-Y. Du, J-W. Cui, Q. Chu,

Journal of Thoracic Oncology（2023）

引用0浏览0引用

RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC)

C. M. Rudin, A. Dowlati, Y. Chen,A. F. Navarro Mendivil, J. C-H. Yang, G. Stojanovic, P. Rich, Z. G. Andric,Y-L. Wu, H. Chen, L. Zhang, S. Yeung,

JOURNAL OF THORACIC ONCOLOGYno. 4 (2023): S129-S130

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn